Current Report Filing (8-k)

Date : 10/06/2017 @ 5:18PM
Source : Edgar (US Regulatory)
Stock : Anavex Life Sciences Corp. (AVXL)
Quote : 2.73  0.17 (6.64%) @ 6:16PM

Current Report Filing (8-k)

Washington, D.C. 20549


Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2017

(Exact name of registrant as specified in its charter)

Nevada 000-51652 98-0608404
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)


51 West 52nd Street, 7th Floor, New York, NY USA 10019
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 1-844-689-3939

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of October 1, 2017, Anavex Life Sciences Corp., a Nevada corporation (the “Company”), entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with Sandra Boenisch, in her continuing capacity as Principal Financial Officer of the Company. The Amended Agreement replaces the prior employment agreement with Ms. Boenisch, dated September 17, 2015 (the “Original Agreement”), which expired as of October 1, 2017.

The Amended Agreement provides for a base salary of $120,000 CAD and clarifies certain of Ms. Boenisch’s duties to the Company, but is otherwise materially similar to the Original Agreement. The Original Agreement is filed as Exhibit 10.92 to the Company’s Annual Report on Form 10-K, filed on December 29, 2015 and is incorporated herein by reference.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  /s/ Christopher Missling
  Name: Christopher Missling, PhD
  Title: Chief Executive Officer
Date: October 6, 2017  





Anavex Life Sciences Corp. (NASDAQ:AVXL)
Historical Stock Chart

1 Year : From Sep 2017 to Sep 2018

Click Here for more Anavex Life Sciences Corp. Charts.

Anavex Life Sciences Corp. (NASDAQ:AVXL)
Intraday Stock Chart

Today : Tuesday 25 September 2018

Click Here for more Anavex Life Sciences Corp. Charts.

Latest AVXL Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.